Myriad and AbbVie Sign Expanded Agreement for Tumor

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Myriad and AbbVie Sign Expanded Agreement for Tumor BRACAnalysis CDx(TM)

SALT LAKE CITY, Nov. 3, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN ) announced today that it has signed an expanded companion diagnostic agreement with AbbVie, Inc. (NYSE: ABBV ), a leading global biopharmaceutical company to use Tumor BRACAnalysis CDx™ as a companion diagnostic in support of AbbVie's novel poly (ADP-ribose) polymerase or PARP inhibitor, veliparib.

The collaboration builds upon Myriad's previous agreements with AbbVie under which the company is providing BRACAnalysis CDx testing to support several of AbbVie's ongoing Phase 3 clinical studies of veliparib, including neo-adjuvant and metastatic breast cancer.

"Myriad's goal is to provide best-in-class patient care, and we believe that Tumor BRACAnalysis CDx will help us deliver on this goal by identifying patients who may respond to breakthrough therapies currently in development," said Peter Meldrum, president and CEO of Myriad. "We are excited to expand our collaboration with AbbVie, an emerging leader in oncology, and believe their choice of Myriad as a commercial partner speaks to our unique ability to provide high quality, high value companion diagnostic testing on a global basis."

About Tumor BRACAnalysis CDx™

Myriad's Tumor BRACAnalysis CDx is the most robust and accurate companion diagnostic test for identifying both germline (hereditary) and somatic (tumor) cancer-causing mutations in the BRCA1 and BRCA2 genes. Tumor BRACAnalysis CDx has undergone significant analytic validation and has been shown to identify up to 50 percent more patients with cancer-causing BRCA 1/2 mutations compared to germline testing alone. Myriad is actively collaborating with leading pharmaceutical companies to use Tumor BRACAnalysis CDx as a companion diagnostic with certain PARP inhibitors, platinum-based drugs and other chemotherapeutic agents. In the United States, the testing will be done at the Company's laboratory in Salt Lake City. In Europe, the CE-marked test will be performed at the Company's Munich laboratory.

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com .

Myriad, the Myriad logo, BART, BRACAnalysis, Tumor BRACAnalysis CDx, Colaris, Colaris AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, HRD, Vectra and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-F, MYGN-G

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to the use of the Company's Tumor BRACAnalysis CDx™ in support of AbbVie's novel poly (ADP-ribose) polymerase or PARP inhibitor, veliparib; AbbVie's use of the Company's Tumor BRACAnalysis CDx as a companion diagnostic test; the Company's belief that Tumor BRACAnalysis CDx will help the Company provide best-in-class patient care by identifying more patients who may respond to these breakthrough therapies; and the Company's strategic directives under the captions "About Tumor BRACAnalysis CDx" and "About Myriad Genetics." These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and pharmaceutical and clinical services may decline or will not continue to increase at historical rates; risks related to our ability to transition from our existing product portfolio to our new tests; risks related to changes in the governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that we may not be successful in transitioning from our existing product portfolio to our new products, such as our myRisk Hereditary Cancer test, which represents the next generation of our existing hereditary cancer franchise; the risk that we may not be able to generate sufficient revenue from our existing tests and our new tests or develop new tests; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with manufacturing our products or operating our laboratory testing facilities; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to increased competition and the development of new competing tests and services; risks related to our projections about the potential market opportunity for our products; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent infringement claims or challenges to the validity of our patents; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading "Risk Factors" contained in Item 1A in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

Media Contact: Ron Rogers (801) 584-3065 Investor Contact: Scott Gleason (801) 584-1143

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fapon’s Enzyme Push Meets Diagnostics Reality at AMP

Updated Category News Views 0

Enzymes rarely get applause at industry meetings, but they can quietly decide whether a diagnostic workflow behaves or becomes a lab headache. Fapon used its AMP 2026 appearance in Seattle to make that unglamorous case: better enzyme design may help assays move faster and keep working when samples get messy. The company wrapped up the November 10–14 meeting after...

Continue Reading
Kawneer’s OptiQ Window Wins a Useful Design Signal

Updated Category News Views 49

Three Nods, One Very Practical Product Claim Windows rarely stir much excitement outside an architect’s specification binder, but Kawneer has put together a respectable run with its OptiQ Offset Fixed/Projected Series Window. On November 18, 2026, the architectural aluminum-systems maker said the product had won in the Windows and Doors category at both the 2026...

Continue Reading
Hexaware’s Seven-Year Client Signal Is Worth Watching

Updated Category News Views 159

Seven straight years of recognition is harder to shrug off than one shiny plaque on a corporate shelf. Hexaware Technologies announced on November 18, 2026 that it received the ISG Star of Excellence Award in the Client Champion category, marking its seventh consecutive year of recognition in that awards program. For investors following IT services, that is a...

Continue Reading
Paladone Tests LEGO's Everyday Collectibles Pull Abroad

Updated Category News Views 71

A glowing minifigure lamp is not exactly a macroeconomic event, but licensed merchandise has a funny way of revealing where household spending still has a pulse. Paladone Products has put its first LEGO-branded collection into stores, a modest-looking launch with some real retail logic behind it. This is not a grand toy-box bet on one blockbuster item. It is a spread of...

Continue Reading
Weatherford Adds Grant Roach to Its Sports Deal Team

Updated Category News Views 40

Sports investing has reached that awkward middle age where everybody sees the runway, but few can explain exactly where the bumps are. Weatherford Capital’s decision to bring Grant Roach aboard as vice president is not a headline packed with transaction fireworks. It is, however, a pretty clear tell: the Tampa firm intends to put more bodies and more underwriting muscle...

Continue Reading
Trinity's Minneapolis Move Signals Freight Momentum

Updated Category News Views 54

A suite change inside downtown Minneapolis is usually wallpaper, but this one carries a little more weight. Trinity Logistics has moved its Minneapolis team from Suite 1850 to Suite 1700 at 100 S. 5th Street, saying the larger space is needed for continued growth and future opportunity. Nobody should confuse an office relocation with a freight-cycle victory lap. Still,...

Continue Reading
Auria, LSAS Team Up: Japan Space Frontier Beckons

Updated Category News Views 105

Pioneering Ventures in Japan's Space Race Watch out, folks—Auria and LSAS Tec have something cooking. One's a titan in space technology, and the other's a maestro in mission analysis. They're joining forces to tango in Japan's booming space market. If you're into the street-smart equity dance, this partnership ain't just chatter over coffee; it's a leap toward new...

Continue Reading
ASUS Brings AI Infrastructure Choices to SC26 Floor

Updated Category News Views 296

Compute buyers are sick of being handed one locked box That is the nerve ASUS is pressing at SC26: enterprises want AI infrastructure that fits the job in front of them, not somebody else's tidy product roadmap. The company is pitching a full-stack “AI Factory” blueprint built across Intel, AMD and NVIDIA hardware, running from rack-scale systems and conventional...

Continue Reading
MobileX's $10 Plan Puts Holiday Pressure on Wireless

Updated Category News Views 255

A sixty-dollar commitment is a small bet, but in wireless it can become a loud little nuisance for every carrier charging far more. MobileX has rolled out a Black Friday offer giving new customers 10GB of high-speed data, unlimited talk and text, and six months of service for $60 upfront. That pencils out to $10 a month, before taxes and government surcharges, and it runs...

Continue Reading
Century's Florence Model Openings Put Arizona in Focus

Updated Category News Views 0

Six furnished houses in Florence may sound like a modest ribbon-cutting, but homebuilding is a business of small field signals before the quarterly numbers ever show up. Century Communities is scheduled to host a November grand opening for six model homes spanning two new communities in Florence, Arizona. For investors tracking NYSE:CCS, that is not a thesis by itself. It...

Continue Reading

Top 5 Most Recently Viewed Articles

Join the Excitement of the Salt Lake Winter Roundup Event

Updated Category News Views 543

Join the Excitement of the Salt Lake Winter Roundup Event Get ready for a fantastic celebration at the Salt Lake Winter Roundup, an event that promises to be a highlight of the winter season. This all-day festival, taking place on Saturday, February 8, 2025, is set to invigorate downtown Salt Lake with an array of activities and cultural events celebrating the area's rich...

Continue Reading
Statkraft's Strategic Moves Lead to NOK 13.5 Billion Sale

Updated Category News Views 238

Statkraft Reports on Key Asset Divestment Statkraft experienced a notable shift in its operations with a significant divestment reported recently. The company's results in the third quarter demonstrated a decline despite increased power production. This downturn was linked to several factors, including low market prices and reduced contributions from its commercial market...

Continue Reading
Unlocking Wealth: Understanding TE Connectivity's Growth Journey

Updated Category News Views 218

Transforming Investment: The Growth of TE Connectivity TE Connectivity (NYSE: TEL) has shown remarkable performance in the stock market, significantly outpacing the broader market indices over the past fifteen years. With an impressive annual return of 13.74%, this company has established itself as a strong contender in the tech and connectivity industries. Investment...

Continue Reading
Hyperlink InfoSystem Leads California's Software Innovation

Updated Category News Views 128

Hyperlink InfoSystem's Impact on California's Tech Scene In the heart of innovation, California continues to be a significant player in the tech industry, home to numerous landmark companies that shape the future of technology. As digital transformation accelerates across industries, the demand for proficient software development partners has never been so urgent....

Continue Reading
Sola Security Secures $35 Million to Transform Cybersecurity

Updated Category News Views 197

Sola Security's Innovative Funding Round Sola Security, an emerging leader in cybersecurity AI, has made headlines by raising $35 million in a recent Series A funding round. This investment follows their successful $30 million seed round earlier, bringing the total funds raised to a remarkable $65 million. The company plans to use these new resources to further enhance...

Continue Reading